Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Рынки
Скринер
Новости
О нас

SGRY - Surgery Partners, Inc. Последние новости | Finranks

Home

SGRY

(SGRY)

NMS – Цена в реальном времени. Валюта: USD

11.49

-0.36 (-3.04%)

При закрытии: Mar 27, 2026, 4:00 PM EDT

12.00

+0.51 (4.44%)

После закрытия: Mar 27, 2026, 6:31 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Видео

No Data

There is no data to display

Пресс-релизы

SGRY: ADJUSTED EBITDA FELL SHY OF MANAGEMENT'S GUIDED PROJECTIONS -- LEVI & KORSINSKY, LLP INVESTIGATES

SGRY: ADJUSTED EBITDA FELL SHY OF MANAGEMENT'S GUIDED PROJECTIONS -- LEVI & KORSINSKY, LLP INVESTIGATES

Surgery Partners reported AN Adjusted EBITDA decline of 4.2% in Q4 following projections for continued expanding margins -- Levi & Korsinsky, LLP investigates potential securities law violations NEW YORK, March 25, 2026 /PRNewswire/ -- Surgery Partners (NASDAQ: SGRY) investors lost money after the Company's Q4 2025 earnings revealed a significant gap between the adjusted figures management highlighted and the Company's GAAP financial results. Shareholders who suffered a loss are encouraged to submit their information here.

SGRY GUIDED FOR MARGIN EXPANSION WHILE HEADWINDS MOUNTED -- LEVI & KORSINSKY, LLP INVESTIGATES

SGRY GUIDED FOR MARGIN EXPANSION WHILE HEADWINDS MOUNTED -- LEVI & KORSINSKY, LLP INVESTIGATES

SURGERY PARTNERS (SGRY) GUIDED FOR MARGIN EXPANSION WHILE HEADWINDS MOUNTED -- LEVI & KORSINSKY, LLP INVESTIGATES Levi & Korsinsky, LLP investigates whether Surgery Partners' forward guidance concealed known cost pressures and operational risks that later drove an earnings miss and guidance downgrade NEW YORK, March 18, 2026 /PRNewswire/ -- Surgery Partners (NASDAQ: SGRY) shareholders watched the stock drop sharply in early March 2026 after Q4 2025 results and FY 2026 outlook both fell short of expectations. Months earlier, CEO Eric Evans told investors on the Q4 2024 earnings call: "we continue to expect margin expansion in 2025 and beyond.

Surgery Partners, Inc. Names Lloyd Dean to Board of Directors

Surgery Partners, Inc. Names Lloyd Dean to Board of Directors

BRENTWOOD, Tenn., March 12, 2026 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”) recently announced that Lloyd Dean has been appointed to serve as an independent director on its Board of Directors.

SGRY: ADJUSTED EBITDA FELL SHY OF MANAGEMENT'S GUIDED PROJECTIONS -- LEVI & KORSINSKY, LLP INVESTIGATES

SGRY: ADJUSTED EBITDA FELL SHY OF MANAGEMENT'S GUIDED PROJECTIONS -- LEVI & KORSINSKY, LLP INVESTIGATES

Surgery Partners reported AN Adjusted EBITDA decline of 4.2% in Q4 following projections for continued expanding margins -- Levi & Korsinsky, LLP investigates potential securities law violations NEW YORK, March 11, 2026 /PRNewswire/ -- Surgery Partners (NASDAQ: SGRY) investors lost money after the Company's Q4 2025 earnings revealed a significant gap between the adjusted figures management highlighted and the Company's GAAP financial results. Shareholders who suffered a loss are encouraged to submit their information here.